会议期间，《肿瘤瞭望》特邀大会日程委员会联合主席，匹兹堡大学医学中心Magee妇女医院Alexander Olawaiye教授及弗吉尼亚大学医学院Paola Gehrig教授接受专访，分享2025 SGO会议亮点及学科未来发展趋势，特此整理，以飨读者。
SGO 2025
微专辑
扫描二维码
可查看更多内容
第56届美国妇科肿瘤学年会（SGO 2025）于2025年3月14-17日在西雅图盛大召开。作为全球范围内最权威的妇科肿瘤学术会议之一，SGO年会将为业内同道提供交流最新研究成果和临床经验的平台，展示具有创新性及前沿视角的观点和思路。
会议期间，《肿瘤瞭望》特邀大会日程委员会联合主席，匹兹堡大学医学中心Magee妇女医院Alexander Olawaiye教授及弗吉尼亚大学医学院Paola Gehrig教授接受专访，分享2025 SGO会议亮点及学科未来发展趋势，特此整理，以飨读者。
《肿瘤瞭望》：作为大会日程委员会联合主席，请您简要介绍一下2025 SGO的总体情况和会议主题？
Alexander Olawaiye教授：2025 SGO以“Multiply your impact（扩大你的影响力）”为主题，该主题由SGO主席Amanda Nickles Fader教授提出，目的是探讨影响妇科肿瘤领域的多维度议题，包括学科现状、前沿科学、患者关怀等，这些要素共同构成了会议的核心框架。我们希望通过这一主题，全面展示能切实推动妇科肿瘤学科发展的核心要点及前沿进展。
Prof.Olawaiye：The meeting of this year was basically developed with the concept of the theme provided by our president，professor Amanda Nickles Fader，which is basically for us to send every aspect of the theme on those things that would impact the field of gynecological oncology，with it is the state of our society，or the science that we all care about，or the care of the patients that we are asked to care for，which is extremely important.So I think the theme of science and everything about the meeting is about those things that are very impactful in all the areas that affect our profession.
《肿瘤瞭望》：请您介绍下本届年会在议程设置和内容安排上有哪些新的亮点和特色？
Paola Gehrig教授：作为致力于推进妇科肿瘤诊疗水平提升及学科发展的盛会，本届SGO年会议题设置广泛，包括创新疗法、预防策略、医疗公平性、外科技术革新及动态医疗格局等。个人认为，最令人期待的环节之一是“Tumor Board:How Can We Leverage AI in Our Tumor Boards and Screening for Clinical Trials?（肿瘤多学科会诊：如何在肿瘤多学科会诊及临床试验筛选中利用AI？）”，这一环节兼具娱乐性及教育性，其深入探讨了AI在妇科肿瘤临床实践中扮演的角色及最新进展。正如Amanda Nickles Fader教授所言，AI是提升医疗可持续性、实现个体化精准治疗的工具，而个体化医疗是促进医疗公平的重要方式。我们期待通过这一环节，展现AI在加速临床决策创新中可应用的场景及价值。
Prof.Gehrig:I think one of the most exciting things is we’re actually going to have a tumor board that is going to feature——Is AI smarter than our bridges scholars?So this is gonna be really entertaining，but still very educational and cutting-edge.What is the role of AI as we heard from our speakers that AI is just a tool.It is a way of making our profession more sustainable and a way of creating some amount of individuality and personalizing the care that we provide.As was stated earlier today by doctor Fader，personalized medicine is a way to create equity.So I think that’s gonna be a really exciting session.
《肿瘤瞭望》：您认为本届年会上最值得关注的学术热点和研究进展有哪些？
Paola Gehrig教授：本次大会将披露众多令人振奋的研究成果。首先我们应该关注妇科肿瘤领域的临床研究进展，因为这些成果将会成为未来改善患者生存的重要依据。随着医学技术的不断进步，妇科肿瘤的诊断和治疗已经进入了精准个体化治疗时代，这将推动着临床研究策略的不断革新。如针对铂耐药卵巢癌患者，不同患者人群对不同药物组合的疗效差异显著，未来亟需通过发现新的生物标志物以精准预测获益人群。其次，靶向治疗与AI技术的结合将推动个性化医疗的发展，如通过AI加速药物筛选与临床试验设计等。
Prof.Gehrig:There’s still a lot more exciting science to come.We’re only a day and a half into it.We have another day and a half to go for the meeting.But I think some of common themes are emerging.And I think what we focus on is about the clinical trials，that is how we’re gonna move forward with the improving the outcomes for our patients.As we think about clinical trials，not one size fits all.And as we had learned in our last session，there are some interesting findings that while we can’t prove it because that they are hypothesis generating.So if we think about our patients with platinum resistant ovarian cancer，there are clearly some patients that are gonna be benefit more from one cocktail of medications versus another.And how do we predict who those patients are gonna be?So I think the targeted therapy，we’re really just on the cusp of that.And I think incorporating AI into that so we can m
